Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03113500 · ClinicalTrials.gov registry record · Phase 2
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma
A Phase 2 study of Angioimmunoblastic T-cell Lymphoma and Hepatosplenic T-cell Lymphoma, sponsored by City of Hope Medical Center.
- Active
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
- 5
- Study locations
NCT03113500: Active Phase 2 study of Angioimmunoblastic T-cell Lymphoma and Hepatosplenic T-cell Lymphoma, sponsored by City of Hope Medical Center.
NCT03113500 is a Phase 2 study of Angioimmunoblastic T-cell Lymphoma and Hepatosplenic T-cell Lymphoma that is active but no longer recruiting, run by City of Hope Medical Center. The registered enrollment target is 48 participants, below the 68-participant average among 21 other Angioimmunoblastic T-cell Lymphoma trials with a reported enrollment target (29% lower). The trial reports 5 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03113500, a Phase 2 study of Angioimmunoblastic T-cell Lymphoma and Hepatosplenic T-cell Lymphoma, is active but no longer recruiting, sponsored by City of Hope Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
- 5
- Study locations
Study Summary
This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches to CD30 positive cancer cells in a targeted way and delivers vedotin to kill them. Drugs used in chemotherapy, such as cyclophosphamide, doxorubicin, etoposide, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving brentuximab vedotin and combination chemotherapy may work better in treating patients with CD30-positive peripheral T-cell lymphoma.
Primary Outcome
CR rate was estimated by the proportion of evaluable patients achieving CR after CHEP-BV induction therapy, along with the 95% exact binomial confidence interval.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Doxorubicin
- DRUG Doxorubicin Hydrochloride
- DRUG Etoposide
- DRUG Brentuximab Vedotin
Study Locations (5)
California
- City of Hope Comprehensive Cancer Center - Duarte
New Jersey
- Hackensack University Medical Center - Hackensack
Ohio
- Ohio State University Comprehensive Cancer Center - Columbus
Texas
- M D Anderson Cancer Center - Houston
British Columbia
- BCCA-Vancouver Cancer Centre - Vancouver
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2017-05-25 |
| Est. Completion | 2026-07-07 |
| Phase | Phase 2 |
What the registry record for NCT03113500 still lists
NCT03113500 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 48 participants, a relatively small participant target, below the 68-participant average among 21 other Angioimmunoblastic T-cell Lymphoma trials with a reported enrollment target (29% lower).
The record links to 10 conditions, with Angioimmunoblastic T-cell Lymphoma appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT03113500 lists 5 locations in 5 states (California, New Jersey, Ohio).
Frequently Asked Questions
What is clinical trial NCT03113500 about?
NCT03113500 is a clinical study titled "Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma". This phase II trial studies the side effects and how well brentuximab vedotin and combination chemotherapy work in treating patients with CD30-positive peripheral T-cell lymphoma. Brentuximab vedotin is a monoclonal antibody, brentuximab, linked to a toxic agent called vedotin. Brentuximab attaches ...
What is the current status of trial NCT03113500?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2017-05-25. Estimated completion is 2026-07-07.
What conditions does trial NCT03113500 study?
This clinical trial studies the following conditions: Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Adult T-cell Leukemia/Lymphoma, Enteropathy-Associated T-Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma.
What interventions are being tested in trial NCT03113500?
The interventions under investigation include: Cyclophosphamide (DRUG), Doxorubicin (DRUG), Doxorubicin Hydrochloride (DRUG), Etoposide (DRUG), Brentuximab Vedotin (DRUG).
Who is sponsoring clinical trial NCT03113500?
This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03113500 being conducted?
This trial has 5 study locations across California, New Jersey, Ohio, Texas, British Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Angioimmunoblastic T-cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03113500's enrollment target sits among peer trials
48 8th of 21 higher than 14 of 21 other Angioimmunoblastic T-cell Lymphoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Angioimmunoblastic T-cell Lymphoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
ACTIVE NOT RECRUITING · Phase 2
-
Sorafenib Tosylate in Treating Patients With Recurrent Aggressive Non-Hodgkin's Lymphoma
COMPLETED · Phase 2
-
Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
COMPLETED · Phase 2
-
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
COMPLETED · Phase 2
-
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
COMPLETED · Phase 2
-
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01765777 · 48 participants · NA
Efficacy of Osteopathic Manipulative Medicine (OMM) and Phototherapy for Patients With Chronic Lower Back Pain
- NCT03073343 · 48 participants · NA
A Prospective, Randomized, Open Label Trial of Two Doses of Oral Betaine
- NCT03431064 · 48 participants
Lung Recruitment Maneuver as a Potential Predictor of Fluid Responsiveness in Mechanically Ventilated Pediatric Patients
- NCT03514602 · 48 participants · NA
Maternal Smoking Cessation and Pediatric Obesity Prevention
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI